SARS-CoV-2 peptides and proteins with reduced adherence to Angiotensin Converting Enzyme-2

Patent number:

EP21382574.8

Reino de Navarra.svg
No items found.

The present invention refers to a mutated amino acid sequence, a mutated receptor-binding domain and a mutated Spike protein of SARS-CoV-2 with reduced adherence to Angiotensin Converting Enzyme-2 (ACE-2), antibodies that specifically binds to them, pharmaceutical and/or veterinary compositions comprising them, nucleic acids that encode them and therapeutic and prophylactic uses. In particular, the present invention refers to their uses in the prophylaxis and/or treatment of a SARS-CoV-2 infection and COVID disease.

Countries:
Spain
Regions:
Navarre
Centers:
UNIVERSIDAD PUBLICA DE NAVARRA
Other entities:
Navarrabiomed (Centro de Investigación Biomédica)
Sectors:
Health
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
BRL1: Hypothesizing on possible business concept
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

La variante del Spike de SARS-CoV-2 desarrollada preserva la mayor parte del sitio de unión a ACE-2, multiplica la concentración del inmunógeno en los nódulos linfáticos, aumenta el título de anticuerpos neutralizantes y reduce el potencial riesgo asociado al bloqueo de receptores ACE-2 debido a la propia vacunación. Mejora de la vacunación frente a SARS-CoV-2 y enfermedad COVID.

Comments

Other related patents

Health

VACCINE FOR FISH AGAINST HEMORRHAGIC SEPSIS

Countries
Spain
Know more
Health

METHOD AND KIT FOR EVALUATING THE TOXICITY OF A SAMPLE

Countries
Spain
Know more
Health

PROTEASOME INHIBITOR

Countries
Spain
Know more
Get back to patents directory